Skip to content

Alzheimer’s Association International Conference® 2020 (AAIC®)

BioArctic’s partner Eisai presented the latest data from the open-label extension of the Phase 2b study with the investigational Lecanemab back-up in early Alzheimer’s disease. The preliminary results show, among other things, a continuous decrease in amyloid levels in the brain measured at three, six and twelve months with Lecanemab back-up treatment in those patients who had previously received placebo. The frequency of amyloid-related imaging abnormalities-edema (ARIA-E) during Lecanemab back-up treatment to date in the open-label extension study is comparable to the Phase 2b study. The data were presented at the Alzheimer’s Association International Conference® 2020 (AAIC®) on July 29.

The study design of the Phase 3 program AHEAD 3-45 was also presented. In the study, the therapeutic effect of drug candidate Lecanemab back-up (an anti-amyloid beta protofibril antibody) on the progression of preclinical, asymptomatic, Alzheimer’s disease will be investigated.